ocular hypertension/obesity

BACKGROUND OF THE INVENTION This invention relates to cyclic amine phenyl .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to cyclic amine phenyl .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to azolidine derivatives which are .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to arylsulfide, arylsulfoxide and arylsulfone derivatives which are .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or

BACKGROUND OF THE INVENTION This invention relates to azolidine derivatives which are .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to piperidino-phenyl amino squarate and thiadiazole dioxide .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose

BACKGROUND OF THE INVENTION This invention relates to phenyl-oxo-tetrahydroquinolin-3-yl .beta.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to phenyl-oxo-tetrahydroquinolin-3-yl .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance),

BACKGROUND OF THE INVENTION This invention relates to heterocyclic .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal

BACKGROUND OF THE INVENTION This invention relates to 4-substituted piperidine .beta..sub.3 -adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to 4-substituted piperidine .beta..sub.3 -adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to